Abbott’s Confirm Rx insertable cardiac monitor (ICM). Credit: Abbott.

Abbott has launched a new implantable heart monitor, dubbed Confirm Rx, for the detection of arrhythmias in the US and Europe.

Confirm Rx holds US Food and Drug Administration (FDA) clearance and the European CE-Mark.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The paperclip-sized, next-generation insertable cardiac monitor (ICM) features smartphone connectivity and continuous, remote monitoring of irregular heartbeats to enable quick diagnosis.

Arrhythmia is characterised by abnormal heart rhythm, which could result in symptoms such as the feeling of the heart racing, dizziness, shortness of breath or fainting.

The company noted that majority of the patients suffering with the most common form of arrhythmia called atrial fibrillation (AFib) are not even aware of their condition.

“Through new advances like Abbott’s next generation of Confirm Rx ICM, physicians can act more proactively and efficiently in their treatment approach, and patients can stay engaged and connected.”

Existing wearables to monitor cardiac arrhythmias have their limitations. Many require recharging while others require human interventions to record symptoms, thereby affecting clinical diagnosis.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Confirm Rx is designed to help physicians remotely and continuously monitor arrhythmias in people who are at most risk. The device is implanted under the skin in the chest above the heart in a minimally invasive outpatient procedure.

It can be connected to a smartphone via Bluetooth in order to transmit information to the physician. The mobile app eliminates the requirement for an additional transmitter.

Abbott Cardiac Rhythm Management therapies medical director Avi Fischer said: “Through new advances like Abbott’s next generation of Confirm Rx ICM, physicians can act more proactively and efficiently in their treatment approach, and patients can stay engaged and connected.”

The detection technology in the new device minimises false detection by 97% and does not notify physicians of irregular heartbeats that may not be related to an arrhythmia.

The device’s SharpSense technology has been designed based on physician feedback and user insights.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now